VLDL Cholesterol

Your standard cholesterol report gives you an LDL number and moves on. But roughly half the heart attack risk from cholesterol-carrying particles comes not from LDL, but from a larger, triglyceride-loaded particle your liver pumps out called VLDL (very low-density lipoprotein). In a study of over 25,000 adults tracked for more than a decade, VLDL cholesterol accounted for approximately half the myocardial infarction risk tied to all cholesterol-carrying particles combined. If you have only been watching your LDL, you may be missing a substantial piece of your cardiovascular picture.

VLDL is not just another cholesterol number. It reflects how aggressively your liver is packaging and exporting fat into your bloodstream, a process driven by what you eat, how much body fat you carry, and how well your insulin system is working. When VLDL is elevated, it signals that your body's fat-processing machinery is running hot, and the excess cholesterol those particles leave behind in your artery walls can be just as damaging as LDL.

How VLDL Differs from LDL

Both VLDL and LDL belong to the family of particles built around a protein scaffold called apolipoprotein B-100 (apoB). Each VLDL particle carries exactly one copy of this protein, just like each LDL particle does. The difference is cargo: VLDL particles are much larger and loaded primarily with triglycerides (a type of fat), while LDL particles are smaller and carry mainly cholesterol. As VLDL circulates, enzymes strip away its triglycerides, and the particle shrinks into an intermediate form (called IDL) and eventually into LDL.

This matters because the leftover particles from VLDL breakdown, often called remnants, are especially dangerous. Remnant particles can carry up to 40 times more cholesterol per particle than LDL, and they are gobbled up by immune cells in artery walls without the usual safety brakes that regulate LDL uptake. The result is faster plaque buildup.

Heart Attack and Cardiovascular Disease

The evidence linking VLDL cholesterol to heart disease is strong and growing. In the Copenhagen General Population Study, every 1 mmol/L (about 39 mg/dL) increase in VLDL cholesterol was associated with roughly double the risk of heart attack (hazard ratio 2.07), a per-unit risk comparable to LDL cholesterol. The risk climbed continuously with higher VLDL cholesterol, with no safe plateau.

A 15-year study of over 30,000 Chinese adults found that elevated VLDL cholesterol (30 mg/dL or above) increased coronary heart disease risk by 2 to 3 times even among people with normal LDL cholesterol and no other major risk factors. The portion of heart disease in that population attributable to elevated VLDL cholesterol was 17.3%, which exceeded the share attributable to LDL cholesterol alone.

Sources: Balling et al. (Copenhagen General Population Study); Ren et al. (Chinese Multi-Provincial Cohort Study); Seehusen et al. (Rochester Epidemiology Project).

What this means for you: even if your LDL looks fine, an elevated VLDL cholesterol can drive meaningful cardiovascular risk on its own. People whose VLDL is high while LDL is low (a pattern called lipid discordance) had the highest rate of cardiovascular events in one large U.S. cohort: 16.9 events per 1,000 person-years. A standard lipid panel that focuses only on LDL can miss this entirely.

The Obesity Connection

VLDL cholesterol appears to be one of the key links between excess body weight and heart attack risk. In a study of over 29,000 individuals from the Copenhagen General Population Study, cholesterol carried in VLDL particles explained roughly 40% of the excess heart attack risk associated with higher body mass index, after adjusting for other factors. By contrast, LDL cholesterol did not explain the excess obesity-related risk at all.

This makes biological sense. Insulin resistance, which accompanies most forms of obesity, drives the liver to overproduce VLDL particles and slows their clearance from the bloodstream. The result is a buildup of triglyceride-rich, cholesterol-laden VLDL and its remnants, exactly the particles that fuel plaque growth.

Insulin Resistance, Diabetes, and Metabolic Syndrome

Elevated VLDL is a hallmark of the metabolic dysfunction that precedes and accompanies type 2 diabetes. When your cells stop responding normally to insulin, fat tissue releases more fatty acids into the bloodstream, the liver uses those fatty acids to build more VLDL particles, and the enzymes that normally clear VLDL work less efficiently. This creates what cardiologists call the "atherogenic triad": high triglycerides, low HDL, and small, dense LDL particles, all of which trace back to VLDL overproduction.

If you already have prediabetes or diabetes, your VLDL cholesterol can help explain why cardiovascular risk stays elevated even after you get your LDL to target. The dyslipidemia of diabetes is fundamentally a VLDL problem.

Liver Fat and NAFLD

VLDL triglycerides are preferentially associated with non-alcoholic fatty liver disease (NAFLD) risk, while VLDL cholesterol is more closely tied to heart attack risk. Both fractions of the VLDL particle matter, but for different reasons. An elevated VLDL on your lab report may reflect not only cardiovascular risk but also a liver that is accumulating excess fat, a condition present in roughly one in three adults.

Reference Ranges

VLDL cholesterol on a standard lipid panel is not directly measured. It is calculated from your triglyceride level, traditionally using the formula VLDL-C = triglycerides divided by 5. This estimate works reasonably well when triglycerides are below about 400 mg/dL, but it becomes increasingly inaccurate above that level. Newer formulas, including the Sampson equation (which divides triglycerides by about 8.6 and factors in non-HDL cholesterol), provide better accuracy, especially when triglycerides are elevated.

Because VLDL cholesterol is a calculated value, reference ranges are less standardized than for LDL or HDL. The tiers below are drawn from population studies and clinical literature. Your lab may use slightly different cutpoints depending on the formula it applies.

These tiers are drawn from published research. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. Men tend to have somewhat higher VLDL cholesterol than women at most ages. Both sexes see an increase with age, with women showing an inflection around menopause. African American populations tend to have lower VLDL cholesterol and triglycerides than White populations, while Mexican American populations tend to have higher levels.

Tracking Your Trend

A single VLDL cholesterol reading can be misleading. The biological variability for VLDL-related measurements is high, with a within-person coefficient of variation estimated at roughly 30 to 48% on an unrestricted diet. That means the same person, tested on two different days under normal conditions, could see readings that differ by a third or more. Controlling diet reduces this variability substantially (to around 20 to 23%), which is why fasting and dietary consistency before testing matter.

Because of this variability, a single elevated reading does not mean your VLDL is permanently high, and a single normal reading does not guarantee you are in the clear. The most useful approach is serial tracking: get a baseline, retest in 3 to 6 months if you are making dietary or lifestyle changes, and then check at least annually. What you are looking for is a trend. A VLDL cholesterol that is drifting upward over several readings is a far more reliable signal than any single number.

If you start an intervention intended to lower VLDL (such as reducing refined carbohydrates or adding regular exercise), retesting after 8 to 12 weeks gives you enough time to see a real effect emerge from the noise of day-to-day biological variation.

When Results Can Be Misleading

The high biological variability of VLDL cholesterol means several common situations can distort a single reading. Knowing these confounders helps you avoid overreacting to a result that does not reflect your true baseline.

• Fasting status: VLDL production by the liver is roughly 74% higher in the fed state compared to the fasted state. A non-fasting blood draw will typically show higher VLDL cholesterol. If your lab does not specify fasting, ask, and try to fast consistently (at least 9 to 12 hours) for each draw to make readings comparable.
• Recent exercise: A single bout of moderate-intensity exercise can lower VLDL cholesterol by 20 to 30% for up to 24 to 48 hours afterward by speeding up VLDL clearance. If you exercised intensely the day before your blood draw, your result may look artificially low. For the most representative reading, avoid vigorous exercise for 24 hours before testing.
• Acute illness: Infections and surgery can shift VLDL levels in both directions. During an acute infection, VLDL can increase by roughly 18% during recovery. Guidelines recommend waiting until acute conditions resolve before interpreting lipid results.
• Medications that inflate VLDL without reflecting true metabolic risk: Corticosteroids (such as prednisone) increase VLDL cholesterol by about 47% within two weeks by boosting liver fat production, but these effects reverse within two weeks of stopping the drug. Oral estrogens, retinoids (like isotretinoin), thiazide diuretics, and certain beta-blockers can also raise VLDL as a side effect. If you are on any of these medications, your VLDL cholesterol may overestimate your baseline metabolic risk.

There is also a time-of-day effect. VLDL cholesterol tends to be higher after evening meals than after daytime meals, reflecting circadian variation in liver fat production. If you are tracking trends, try to get your blood drawn at roughly the same time each visit.